Phillips Anne M.'s Form 4 filing
Barinthus Biotherapeutics plc. (BRNS) · filed Sep 9, 2026
- Accession no.
- 0001104659-26-106341
- Filed
- Sep 9, 2026, 4:20 PM ET
- Trade date
- Sep 9, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 5 derivative transactions. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Phillips Anne M.CIK 0001627680 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −3,000 | –F3 | – | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −34,328 | $0.00 | $0 | 0 | Direct | |
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −18,604 | $0.00 | $0 | 0 | Direct | |
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −19,197 | $0.00 | $0 | 0 | Direct | |
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −19,516 | $0.00 | $0 | 0 | Direct | |
| Sep 9, 2026 | Ordinary Shares | DReturned to the companyDisposed | −20,174 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
Referenced by the price of 1 transaction in Table I.